Thomas Steyer Farallon Capital Management
Thomas Steyer founded Farallon Capital Management, a pioneering multi-strategy firm spanning credit, equities, real estate, and event-driven investing. Farallon became known for rigorous research and opportunistic capital allocation across cycles. Although Steyer later focused on public advocacy, the Farallon name remains important in hedge fund history and ongoing 13F tracking.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$546M |
| 2 |
Willis Towers Watson
WTW
|
+$471M |
| 3 |
Mastercard
MA
|
+$344M |
| 4 |
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
|
+$240M |
| 5 |
BBL
BHP Group Plc American Depositary Shares (Each representing two Ordinary Shares)
BBL
|
+$238M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
TIF
Tiffany & Co.
TIF
|
+$301M |
| 2 |
New York Times
NYT
|
+$209M |
| 3 |
Visa
V
|
+$194M |
| 4 |
Elevance Health
ELV
|
+$145M |
| 5 |
AbbVie
ABBV
|
+$123M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 35.71% |
| 2 | Technology | 14.95% |
| 3 | Financials | 13.65% |
| 4 | Communication Services | 11.15% |
| 5 | Industrials | 7.16% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Sherwin-Williams
SHW
$84.1B
| $292M | 1.45% |
1,185,423
+17,325
| +1% | +$4.13M |
|
27
TransUnion
TRU
$16.2B
| $284M | 1.41% |
3,160,077
+1,425,995
| +82% | +$129M |
|
28
Charter Communications
CHTR
$17.9B
| $280M | 1.39% |
454,178
-92,753
| -17% | -$58M |
|
|
GWPH
29
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
| $277M | 1.38% |
+1,278,900
| New | +$240M |
|
|
30
Visa
V
$693B
| $277M | 1.38% |
1,308,829
-919,275
| -41% | -$194M |
|
|
MXIM
31
DELISTED
Maxim Integrated Products
MXIM
| $270M | 1.34% |
2,957,400
+1,415,000
| +92% | +$130M |
|
|
AMRS
32
DELISTED
Amyris Inc.
AMRS
| $258M | 1.28% |
13,500,000
-4,000,000
| -23% | -$58M |
|
33
Exelixis
EXEL
$13.4B
| $243M | 1.21% |
10,750,000
-250,000
| -2% | -$5.65M |
|
34
Hilton Worldwide
HLT
$73.5B
| $236M | 1.17% |
1,949,437
+309,000
| +19% | +$35.7M |
|
|
BBL
35
DELISTED
BHP Group Plc American Depositary Shares (Each representing two Ordinary Shares)
BBL
| $231M | 1.15% |
+4,000,521
| New | +$238M |
|
36
New Oriental
EDU
$8.88B
| $223M | 1.11% |
1,594,300
+440,000
| +38% | +$76.9M |
|
37
Fate Therapeutics
FATE
$279M
| $157M | 0.78% |
1,900,000
-1,100,000
| -37% | -$105M |
|
38
Alibaba
BABA
$286B
| $153M | 0.76% |
676,400
-176,900
| -21% | -$43.4M |
|
39
Iovance Biotherapeutics
IOVA
$3.76B
| $150M | 0.75% |
4,750,000
-1,250,000
| -21% | -$51.8M |
|
|
MRTX
40
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $146M | 0.72% |
850,000
-25,000
| -3% | -$4.95M |
|
41
Lufax Holding
LU
$1.2B
| $143M | 0.71% |
2,458,350
+1,118,912
| +84% | +$68.7M |
|
42
Ascendis Pharma A/S
ASND
$16.6B
| $129M | 0.64% |
1,000,000
| – | – |
|
43
Qiagen
QGEN
$9.1B
| $124M | 0.61% |
2,393,874
-677,442
| -22% | -$37.2M |
|
|
44
New York Times
NYT
$10.6B
| $120M | 0.6% |
2,379,622
-4,165,707
| -64% | -$209M |
|
45
Equifax
EFX
$22.6B
| $110M | 0.55% |
606,629
+235,945
| +64% | +$41.7M |
|
|
PLYA
46
DELISTED
Playa Hotels & Resorts
PLYA
| $109M | 0.54% |
14,994,867
| – | – |
|
47
Alnylam Pharmaceuticals
ALNY
$31.6B
| $98.8M | 0.49% |
700,000
+350,000
| +100% | +$52.7M |
|
48
Enanta Pharmaceuticals
ENTA
$392M
| $98.4M | 0.49% |
1,995,000
+220,000
| +12% | +$11M |
|
49
Howmet Aerospace
HWM
$108B
| $95M | 0.47% |
2,955,729
-1,935,750
| -40% | -$55.7M |
|
|
APLS
50
DELISTED
Apellis Pharmaceuticals
APLS
| $93.3M | 0.46% |
2,175,000
-100,000
| -4% | -$4.73M |
|
Similar funds
Thomas Steyer's Q1 2021 Portfolio in Review
As of Q1 2021, Thomas Steyer held 257 positions worth $20.1B, up 21% from $16.6B the previous quarter. Its ten largest holdings account for 33% of the portfolio.
Thomas Steyer deployed $2.5B of net new capital in Q1 2021, opening 120 new positions and adding to 40 existing holdings. Its largest new stake was Mastercard: 985,920 shares worth $351M.
By sector, the portfolio is most concentrated in Healthcare at 36% of assets, down from 39% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was New York Times, an estimated $209M trimmed.
- Thomas Steyer's largest Q1 2021 buy was Mastercard: 985,920 shares worth $351M.
- Thomas Steyer added most to Alexion Pharmaceuticals in Q1 2021, an estimated $546M increase.
- Thomas Steyer's biggest Q1 2021 reduction was New York Times, cutting an estimated $209M.
- Thomas Steyer fully exited Tiffany & Co. in Q1 2021, selling an estimated $301M.
- Thomas Steyer's ten largest holdings make up 33% of its $20.1B portfolio in Q1 2021.
- Thomas Steyer opened 120 new positions and closed 20 in Q1 2021.
- Thomas Steyer's portfolio value rose 21% quarter-over-quarter to $20.1B.
Based on Farallon Capital Management's 13F filing for Q1 2021, filed 17 May 2021.